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OBJECTIVE—Calcium dobesilate (CaD) has been used in the
treatment of diabetic retinopathy in the last decades, but its
mechanisms of action are not elucidated. CaD is able to correct
the excessive vascular permeability in the retina of diabetic
patients and in experimental diabetes. We investigated the mo-
lecular and cellular mechanisms underlying the protective effects
of CaD against the increase in blood–retinal barrier (BRB)
permeability induced by diabetes.
RESEARCH DESIGN AND METHODS—Wistar rats were di-
vided into three groups: controls, streptozotocin-induced dia-
betic rats, and diabetic rats treated with CaD. The BRB
breakdown was evaluated using Evans blue. The content or
distribution of tight junction proteins (occludin, claudin-5, and
zonula occluden-1 [ZO-1]), intercellular adhesion molecule-1
(ICAM-1), and p38 mitogen-activated protein kinase (p38 MAPK)
was evaluated by Western blotting and immunohistochemistry.
Leukocyte adhesion was evaluated in retinal vessels and in vitro.
Oxidative stress was evaluated by the detection of oxidized
carbonyls and tyrosine nitration. NF-B activation was measured
by enzyme-linked immunosorbent assay.
RESULTS—Diabetes increased the BRB permeability and reti-
nal thickness. Diabetes also decreased occludin and claudin-5
levels and altered the distribution of ZO-1 and occludin in retinal
vessels. These changes were inhibited by CaD treatment. CaD
also inhibited the increase in leukocyte adhesion to retinal
vessels or endothelial cells and in ICAM-1 levels, induced by
diabetes or elevated glucose. Moreover, CaD decreased oxidative
stress and p38 MAPK and NF-B activation caused by diabetes.
CONCLUSIONS—CaD prevents the BRB breakdown induced
by diabetes, by restoring tight junction protein levels and orga-
nization and decreasing leukocyte adhesion to retinal vessels.
The protective effects of CaD are likely to involve the inhibition
of p38 MAPK and NF-B activation, possibly through the inhibi-
tion of oxidative/nitrosative stress. Diabetes 59:2637–2645,
2010
T
he blood–retinal barrier (BRB) breakdown is the
hallmark of diabetic retinopathy (1). Alterations
in BRB occur early in the progression of diabetic
retinopathy and eventually lead to macular
edema, which is responsible for vision loss (2). The
increase in BRB permeability is associated with changes in
the expression, content, phosphorylation, and distribution
of tight junction proteins in retinal vessels (3–7), as well as
with increased vesicular transport mediated by endocy-
totic vesicles (8).
Occludin and claudins are responsible for the direct
cell-to-cell attachment in the tight junction barrier (9,10)
and are a crucial determinant of tight junction permeabil-
ity properties in endothelial cells (11,12). Claudin-5 is
necessary to preserve the vascular barrier to small (0.8
kDa) molecules in the brain (13), and it possibly also plays
a similar role in the BRB. The zonula occluden proteins
(ZO-1, -2, and -3) coordinate the assembly of the junctional
complex and provide the interaction with components of
the cytoskeleton (14), also important for BRB function.
Diabetes causes metabolic and physiologic abnormali-
ties in the retina, and it appears that inﬂammation plays a
critical role in the development of diabetic retinopathy.
Those changes include the upregulation of inducible nitric
oxide synthase, cyclooxygenase-2, intercellular adhesion
molecule-1 (ICAM-1), caspase-1, vascular endothelial
growth factor (VEGF), and nuclear factor kappa B (NF-
B), as well as increased production of nitric oxide,
prostaglandin E2, and cytokines (15,16). We and others
also demonstrated that the adhesion of leukocytes to
retinal vessels is increased in the retinas of diabetic
animals, and this increase is correlated with changes in
tight junction proteins and increased BRB permeability
(4,6,8,17,18). The increase in leukostasis is also associated
with an increase in the expression of ICAM-1 by retinal
endothelial cells (18,19). NF-B regulates the expression
of adhesion molecules, such as ICAM-1, and NF-B acti-
vation has been correlated with the increase in leukostasis
and BRB breakdown in diabetic rat retinas (20). Moreover,
the p38 mitogen-activated protein kinase (p38 MAPK), a
stress-activated serine/threonine protein kinase, is acti-
vated in response to proinﬂammatory cytokines and oxi-
dative stress. The activation of p38 MAPK has been
reported in the retinas of diabetic rats and is associated
with BRB breakdown (21).
Calcium dobesilate (CaD) is considered an angioprotec-
tive drug, and it has been used in the treatment of diabetic
retinopathy and chronic venous insufﬁciency in several
countries during the last few decades (22,23), but its
efﬁcacy in the treatment of diabetic retinopathy is still a
From the
1Center of Ophthalmology and Vision Sciences, IBILI, Faculty of
Medicine, University of Coimbra, Coimbra, Portugal;
2AIBILI, Coimbra,
Portugal; the
3Center for Neuroscience and Cell Biology, University of
Coimbra, Coimbra, Portugal; and
4OM Pharma, Geneva, Switzerland.
Corresponding author: Ermelindo C. Leal, eleal@ibili.uc.pt.
Received 8 October 2009 and accepted 6 July 2010. Published ahead of
print at http://diabetes.diabetesjournals.org on 13 July 2010. DOI:
10.2337/db09-1421.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2637matter of controversy. Several clinical studies have shown
a slowdown of the progression of diabetic retinopathy
after long-term oral treatment with CaD. Its clinical effec-
tiveness occurs mainly through a correction of the exces-
sive vascular permeability in the retina (24,25). CaD
decreases albumin leakage in the retina of diabetic ani-
mals (26), supporting its beneﬁcial effects in BRB perme-
ability. Other studies did not ﬁnd beneﬁcial effects in
patients with diabetic retinopathy (27–29), but patients
were treated with lower doses of CaD and for shorter
periods (6–12 months). Recently, in a follow-up study
(CALDIRET) of ﬁve years involving 635 patients with
mild-to-moderate nonproliferative diabetic retinopathy,
treatment with CaD was not able to reduce macular edema
(30).
Despite the use of CaD in the treatment of diabetic
retinopathy in the last few decades, very low attention has
been given to the molecular and cellular mechanisms
underlying its vascular protective effects. In diabetic rats,
the protective effect of CaD against BRB leakage was
correlated with a decrease in the levels of advanced
glycation end products and VEGF in the retina (26). It also
has been suggested that the beneﬁcial effects of CaD might
be due to its antioxidant properties (31,32). The present
study aimed to clarify the molecular and cellular mecha-
nisms underlying the protective effect of CaD against BRB
permeability induced by diabetes. We evaluated for the
ﬁrst time whether CaD efﬁcacy, in the early stages of
diabetes, is linked to its effects on tight junctions and
leukostasis. Moreover, its effects on the activation of p38
MAPK and NF-B pathways, and on oxidative and nitro-
sative stress, were also addressed.
RESEARCH DESIGN AND METHODS
Materials and reagents used to carry out the experiments are described in the
supplementary Materials and Methods, available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-1421/DC1.
Animal model. All procedures involving animals were conducted in accor-
dance with the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Diabetes was induced in 8–9-week-old male Wistar rats with
an intraperitoneal injection of streptozotocin (65 mg/kg, in 10 mmol/l citrate
buffer, pH 4.5). Two days later, animals with blood glucose levels 250 mg/dl
were considered diabetic. The experiments were performed 1 month after
diabetes induction.
The animals were divided into three groups (7–9 animals/group): control,
diabetics, and diabetics treated with CaD (100 mg/kg/day; orally given) during
the last 10 days of diabetes. We also evaluated the effect of CaD on weight,
blood glucose levels, retinal vascular permeability, retinal thickness, leuko-
cyte adhesion to retinal vessels, tight junction protein content and localiza-
tion, ICAM-1 content, formation of oxidized carbonyls and nitrotyrosine
residues in proteins, and p38 MAPK and NF-B activation. The results were
similar to those obtained with control animals.
Measurement of BRB permeability. BRB permeability was quantiﬁed with
Evans blue, which binds to the plasma albumin, using the method described
by Xu and colleagues (33), with some modiﬁcations. A more detailed
description can be found in the supplementary Materials and Methods.
Retinal thickness. Retinal thickness was determined in retinal sections
stained with hematoxylin/eosin as described in the supplementary Materials
and Methods.
Visualization of retinal vessel leakage. Retinal vascular leakage was
visualized using Evans blue. Under anesthesia, the rats were administered
Evans blue (100 mg/kg) via tail vein and kept on a warm pad for 60 min. The
eyes were enucleated and ﬁxed with 2% paraformaldehyde in PBS for 2 h. The
retina was isolated, ﬂat-mounted, and examined under a confocal microscope
(LSM 510, Carl Zeiss, Gottingen, Germany) to check for Evans blue extrava-
sation from retinal vessels.
Western blot analysis. Western blotting of cellular lysates was performed as
detailed in the supplementary Materials and Methods.
Immunolocalization of occludin, claudin-5, and ZO-1 in retinal vessels.
The retinas were isolated (three animals) and immersed in 2% paraformalde-
hyde for 2  5 min at room temperature. After washing 2  5 min in PBS with
0.3% Triton X-100, the retinas were immersed in blocking solution (6% goat
serum) in PBS with 0.3% Triton X-100 for 30 min, and then incubated for 3 days
at 4°C with anti-occludin (1:100), anti-claudin-5 (1:100), or anti-ZO-1 (1:100)
antibodies. After incubation, the retinas were washed for 24 h and incubated
with an Alexa 488-conjugated secondary antibody (goat anti-rabbit IgG, 1:250)
in PBS with 0.3% Triton X-100. After incubation, the retinas were washed and
ﬂat-mounted for visualization under a confocal microscope (LSM510, Carl
Zeiss, Gottingen, Germany).
Leukocyte labeling. Leukocyte suspensions were obtained from the spleen
of normal Wistar rats. The cells were resuspended in 20 ml of complete
medium [RPMI 1,640 supplemented with 10% heat-inactivated FCS, 1% sodium
pyruvate, 4 mmol/l L-glutamine, 1 nonessential amino acids]. To label the
cells, 2  10
7 cells/ml were incubated with 40 g/ml calcein-AM for 30 min at
37°C (34). Calcein-AM is nontoxic and has no effect on cell adhesion (35). The
cells were washed, and 4  10
7 leukocytes in 200 l RPMI were adoptively
transferred into each rat through the tail vein.
Leukocyte adhesion to retinal vessels in whole-mounted retinas. Ap-
proximately 30 min after labeled leukocytes injection, Evans blue (100 mg/kg)
was injected through the tail vein. Thirty min later, the animals were perfused
with citrate-buffered 4% paraformaldehyde (37°C), and then the eyes were
removed and immersed in 2% paraformaldehyde for2ha troom temperature.
The retinas were dissected, ﬂat-mounted, and analyzed by confocal micros-
copy (LSM 510, Carl Zeiss, Gottingen, Germany) to count the leukocytes
adhering to retinal vessels.
Retinal endothelial cell culture. Rat retinal endothelial cells (TR-iBRB2 cell
line) (36) were cultured in low-glucose Dulbecco’s modiﬁed Eagle’s medium
containing 10% FBS, 17.8 mmol/l sodium bicarbonate, 0.1 mg/ml streptomycin,
and 100 units/ml penicillin. Cells were maintained at 33°C in a humidiﬁed
atmosphere of 5% CO2/air. Cells were incubated with 24.5 mmol/l glucose (30
mmol/l ﬁnal concentration) or with mannitol (24.5 mmol/l  5.5. mM glucose;
osmotic control) for 4 days. Endothelial cells were also incubated with 12.5,
25, and 50 g/ml of CaD for 4 days.
In vitro leukocyte adhesion. Endothelial cells were plated in a 24-well plate
for 4 days. Leukocytes were harvested and labeled with Calcein-AM. The
suspension of leukocytes was added to the monolayer of endothelial cells (2 
10
6 leukocytes/well) for 90 min at 37°C. After incubation, nonadherent cells
were removed by gentle washing with RPMI. The emitted ﬂuorescence
(arbitrary units) of adherent leukocytes was measured in a ﬂuorescence plate
reader (excitation wavelength, 490 nm; emission wavelength, 530 nm).
Detection of oxidized carbonyls in proteins. We used the 2,4-dinitrophe-
nylhydrazone (DNP) to examine the direct oxidative injury to proteins. DNP
speciﬁcally reacts with the oxidized carbonyl residues present in proteins. A
more detailed description can be found in the supplementary Materials and
Methods.
NF-B activation. Activation of NF-B was determined in retinal extracts by
enzyme-linked immunosorbent assay, using a NF-B transcription factor kit
(Active Motif, Rixensart, Belgium), following the manufacturer’s instructions,
as brieﬂy described in the supplementary Materials and Methods.
Immunohistochemistry in retinal sections. The formation of nitrotyrosine
residues in the retina was evaluated in retinal sections by immunohistochem-
istry, as described in the supplementary Materials and Methods.
Data are expressed as mean  SEM. Statistical signiﬁcance was deter-
mined by ANOVA, followed by Dunnett or Bonferroni post hoc test, as
indicated in ﬁgure legends.
RESULTS
CaD inhibits the increase in BRB permeability and
retinal thickness induced by diabetes. CaD was orally
administered (100 mg/kg/day) during the last 10 days of
diabetes (30 days duration). After 1 month of diabetes,
the weight gain in diabetic animals was signiﬁcantly less
when compared with controls (219.5  6.6 and 344.6 
5.8 g, respectively) and the blood glucose levels were
signiﬁcantly higher (496.2  15.0 and 96.3  2.4 mg/dl,
respectively). The weight and the blood glucose levels
in diabetic animals treated with CaD were found to be
similar to the values obtained for diabetic animals
without treatment (217.3  4.5 g and 470.9  20.5 mg/dl,
respectively) (Table 1).
Diabetes increased the BRB permeability in diabetic rats
(4.0  0.6 g Evans blue/g wet wt retina) when compared
with control animals (0.6  0.1 g Evans blue/g wet wt
retina). In diabetic rats treated with CaD, there was a
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Evans blue/g wet wt retina) when compared with diabetic
animals (Fig. 1A). The blood vessel leakage was also
visualized with Evans blue in retina ﬂat mounts. In control
retinas, Evans blue ﬂuorescence was limited to the blood
vessels. In diabetic rats, focal leakage of the dye from
capillaries and larger vessels was detected, and the treat-
ment with CaD prevented this effect (Fig. 1B), corroborat-
ing the data obtained with the quantitative Evans blue
assay. Moreover, CaD inhibited the increase in retinal
thickness induced by diabetes. Diabetic retinas were sig-
niﬁcantly thicker than control retinas (153.0  4.0 vs.
135.7  5.0 m), and no signiﬁcant difference was found in
retinal thickness between diabetic animals treated with
CaD and control animals (145.2  5.6 vs. 135.7  5.0 m)
(Table 2).
CaD prevents the changes in the content and/or
distribution of tight junction proteins in retinal ves-
sels induced by diabetes. Diabetes induced a decrease in
occludin and claudin-5 protein levels to 65.2%  7.5% and
63.2%  5.4% of the control, respectively. However, the
total protein content of ZO-1 in retinal extracts of diabetic
animals was not signiﬁcantly different from the controls.
TABLE 1
Weight and blood glucose levels of control, diabetic, and diabetic
CaD-treated animals
Weight (g)
Glycemia
(mg/dl) N
Control 344.6  5.8 96.3  2.7 29
Diabetic 219.5  6.6*** 496.2  15.0*** 24
Diabetic  CaD 217.3  4.5*** 470.9  20.5*** 26
Diabetic animals (1-month diabetes duration) were treated with CaD
(100 mg/kg) in the last 10 days of diabetes. Weight (g) and blood
glucose levels (mg/dl) were measured before animal sacriﬁce and
represent the mean  SEM. ***P  0.01, signiﬁcantly different from
control; ANOVA (one-way) followed by Dunnett post hoc test.
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FIG. 1. Diabetes increases BRB permeability: protective effect of CaD. A: Quantitative measure of BRB permeability by quantiﬁcation of
extravasated Evans blue. Data are presented as g of Evans blue per retina wet wt (g) and represent the mean  SEM of 7–10 animals. **P <
0.01, signiﬁcantly different from control; ANOVA (one-way) followed by Dunnett post hoc test. #P < 0.05, signiﬁcantly different from diabetic;
ANOVA (one-way) followed by Bonferroni post hoc test. B: Representative images showing Evans blue ﬂuorescence, allowing the detection of
leaking sites (arrows) in retinal vessels. In the retina of control animals, Evans blue ﬂuorescence is limited to the blood vessels, while in diabetic
retinas, the dye leaks out of the vessels to the retinal tissue. CaD treatment prevents the leakage of Evans blue. Magniﬁcation: 100; bar 200
m. (A high-quality color representation of this ﬁgure is available in the online issue.)
TABLE 2
Retinal thickness measured in hematoxylin and eosin-stained
retina sections from control, diabetic, and diabetic CaD-
treated animals
Retinal
thickness (m) N
Control 135.7  5.0 6
Diabetic 153.0  4.0* 6
Diabetic  CaD 145.2  5.6 6
Diabetic animals (1-month diabetes duration) were treated with CaD
(100 mg/kg) in the last 10 days of diabetes. The eye sections, from the
proximity of optical disc, were stained with hematoxylin/eosin. The
retinal thickness was measured by image analysis of 5 ﬁelds per
section, from six animals. The results represent the mean  SEM.
*P  0.05, signiﬁcantly different from control; ANOVA (one-way)
followed by Dunnett post hoc test.
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crease in occludin and claudin-5 protein levels induced by
diabetes (98.2%  9.7% and 92.4%  6.2% of the control,
respectively; Fig. 2A and B). In the retinas of CaD-treated
diabetic animals, the protein levels of ZO-1 were also
similar to control values (Fig. 2C). Immunocytochemistry
experiments conﬁrmed these results (Fig. 3). The immu-
noreactivity of occludin and claudin-5 clearly decreased in
the retinal vessels of diabetic animals. In addition, the
localization of occludin and ZO-1, but not of claudin-5,
appears to be altered when compared with the retinas of
control animals. In diabetic animals, occludin and ZO-1
immunostaining in retinal vessels is not so well deﬁned at
endothelial cell borders, when compared with control
animals. Also, in several regions of the vasculature, occlu-
din and ZO-1 appear to accumulate in the cytosol of
endothelial cells. The oral treatment with CaD prevented
the decrease in occludin and claudin-5 immunoreactivity
in retinal vessels induced by diabetes, as well as the
alterations in occludin and ZO-1 localization in endothelial
cells.
Caveolin-1 is an indicator of vascular permeability
through a transcellular transport mechanism. Diabetes
induces caveolin-1 overexpression in the rat retina (8). We
found that diabetes increases caveolin-1 staining, mainly
in the ganglion cell layer. However, CaD treatment did not
prevent the increase in caveolin-1 immunoreactivity (data
not shown).
CaD inhibits leukocyte adhesion to retinal vessels
induced by diabetes. In diabetic animals, there was an
increase in the number of leukocytes adhering to retinal
vessels (38  4 leukocytes/animal) compared with that in
control animals (16  2 leukocytes/animal). In diabetic
rats treated with CaD, there was a signiﬁcant decrease in
the number of adherent leukocytes (26  2 leukocytes/
animal) when compared with diabetic animals (Fig. 4A).
CaD prevents the increase in leukocyte adhesion to
retinal endothelial cells induced by high glucose. We
also evaluated the effect of CaD on the adhesion of
leukocytes to retinal endothelial cells (TR-iBRB2 cell line).
We reported previously that exposure of retinal endothe-
lial cells to elevated glucose (30 mmol/l) for 4 days
increases the adhesion of leukocytes to endothelial cells
(18). As expected, the present data show that high glucose,
but not mannitol (osmotic control), increased the adhe-
sion of leukocytes to endothelial cells (128.7  4.8% of the
control). The exposure of endothelial cells to increasing
concentrations of CaD (12.5, 25, and 50 g/ml) for 4 days
did not alter the adhesion of leukocytes (100.5  3.5%,
96.3  7.5%, and 98.4  9.8% of the control, respectively).
However, 25 and 50 g/ml of CaD, but not 12.5 g/ml,
totally prevented the increase in leukocyte adhesion in-
duced by high glucose (98.7  7.5% and 101.9  7.8% of the
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FIG. 2. CaD prevents the decrease in occludin and claudin-5 protein levels in the rat retinas induced by diabetes. ZO-1 levels were not signiﬁcantly
changed. Tight junction protein levels were assessed by Western blotting. A representative Western blot is shown above each graph. Data are
presented as percentage of control and represent the mean  SEM of 7–9 animals. *P < 0.05, **P < 0.01, signiﬁcantly different from control;
ANOVA (one-way) followed by Dunnett post hoc test.
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FIG. 3. CaD prevents the decrease in occludin and claudin-5 immuno-
reactivity and the changes in occludin and ZO-1 distribution (arrows),
in rat retinal vessels induced by diabetes. Magniﬁcations: 200 (bar
100 m) and 400 (bar 50 m). (A high-quality color representation of
this ﬁgure is available in the online issue.)
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12.5 g/ml) (Fig. 4B).
CaD prevents the upregulation of ICAM-1 levels in
retinal endothelial cells induced by diabetes or high
glucose. The adhesion of leukocytes to retinal vessels is
mediated by the interaction with ICAM-1, which is ex-
pressed in retinal endothelial cells. In the retinas of
diabetic rats, the protein content of ICAM-1 increased to
136.4  12.5% of the control. The upregulation of ICAM-1
induced by diabetes was prevented by CaD treatment (Fig.
4C). Similarly, in retinal endothelial cell cultures, elevated
glucose (30 mmol/l), but not mannitol (osmotic control),
increased the protein levels of ICAM-1 (129.2  6.3% of the
control). Surprisingly, 25 and 50 g/ml of CaD, but not 12.5
g/ml, signiﬁcantly decreased the content of ICAM-1 in
endothelial cells (63.3  3.4% and 63.7  4.0% of the
control, respectively). In addition, 25 and 50 g/ml of CaD
prevented the increase in ICAM-1 levels induced by high
glucose (77.2  7.0% and 70.7  5.2% of the control,
respectively). The lower concentration of CaD used (12.5
g/ml) did not prevent the increase in ICAM-1 content
(135.2  5.2% of the control) (Fig. 4D).
CaD reduces diabetes-induced oxidative and nitrosa-
tive stress. It has been claimed that CaD exerts its
protective effects because of its antioxidant properties
(26,32). Therefore, we evaluated the effects of CaD on the
formation of oxidized carbonyl groups and on tyrosine
nitration in retinal proteins. Oxidative injury to carbonyl
residues signiﬁcantly increased in diabetic retinas
(176.2  18.4% of the control) in comparison with the
controls, and CaD treatment prevented that increase
(110.6  19.3% of the control) (Fig. 5A). Similarly, diabetes
increased tyrosine nitration within retinal layers. The
strongest immunoreactivity against nitrotyrosine residues
was found within the ganglion cell layer (Fig. 5B). Treat-
ment with CaD prevented the increase in tyrosine residues
nitration.
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FIG. 4. Diabetes and elevated glucose increase the number of leukocytes adhering to retinal vessels and retinal endothelial cells and the content
of ICAM-1: protective effect of CaD. A: Quantiﬁcation of leukocytes adhering to retinal vessels. Data are presented as number of adherent
leukocytes to retinal vessels per rat (two retinas) and represent the mean  SEM of seven animals. B: Quantiﬁcation of leukocyte adhesion to
retinal endothelial cells (TR-iBRB2 cell line) using a ﬂuorometric assay. Data are presented as percentage of control and represent the mean 
SEM of 7–10 independent experiments. C: The protein levels of ICAM-1 were evaluated in whole rat retinal extracts by Western blotting. Data
are presented as percentage of control and represent the mean  SEM of seven animals. D: The protein levels of ICAM-1 were evaluated in whole
extracts of rat retinal endothelial cell cultures (TR-iBRB2 cell line) by Western blotting. Data are presented as percentage of control and
represent the mean  SEM of at least four independent experiments. *P < 0.05, **P < 0.01, signiﬁcantly different from control; ANOVA (one-way)
followed by Dunnett post hoc test. #P < 0.05, ##P < 0.01, ###P < 0.001, signiﬁcantly different from diabetic rat or high glucose condition; ANOVA
(one-way) followed by Bonferroni post hoc test. HG, high glucose (30 mmol/l, for 4 days); CaD12.5, CaD25, and CaD50, calcium dobesilate 12.5,
25, and 50 g/ml, respectively (4 days).
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NF-B induced by diabetes. Both p38 MAPK and NF-B
were found to be activated in diabetic retinas, and their
activation has been correlated with changes in BRB per-
meability (20,21). The activation of p38 MAPK, which was
evaluated by the ratio phospho-p38/p38, signiﬁcantly in-
creased in the retinas of diabetic animals (174.1  29.9% of
the control) (Fig. 6A). Diabetes also increased NF-B
activity (129.3  8.4% of the control) (Fig. 6B). Treatment
with CaD prevented the activation of p38 MAPK and
NF-B induced by diabetes (Fig. 6A and B).
DISCUSSION
This is the ﬁrst study clearly showing that CaD inhibits
changes in tight junction proteins, ICAM-1 and leukocyte
adhesion to retinal vessels, which are known to underlie the
increase in BRB permeability. These ﬁndings were correlated
with the inhibition of oxidative/nitrosative stress, and p38
MAPK and NF-B activity.
The potential beneﬁcial effects of CaD on BRB are still
controversial. Several studies have reported vasoprotec-
tive effects of CaD in the early stages of diabetic retinop-
athy (22,24,25). For example, in a double-blind, placebo-
controlled study, a positive effect of CaD (2,000 mg daily
for 2 years) was shown in patients with early diabetic
retinopathy (25). Other studies have reported no beneﬁcial
effects of CaD in the retina of diabetic patients (27–29). In
a recent study (CALDIRET) (30), where mild-to-moderate
nonproliferative diabetic retinopathy patients were fol-
lowed for ﬁve years, CaD failed to reduce diabetic macular
edema. However, this study also shows that, within par-
ticular subgroups of patients, the treatment with CaD can
be beneﬁcial. It appears that the patients with accumula-
tion of risk factors beneﬁt with CaD. Altogether, these
ﬁndings suggest that CaD might be effective in the early
stages of the pathology, losing its efﬁcacy in later stages
(mild-to-moderate nonproliferative diabetic retinopathy),
where macular edema might occur. In the later stages,
CaD will possibly be effective only in some groups of
patients. In animal models, where the duration of diabetes
was relatively short, as is the case of this study, the
beneﬁcial effects of CaD on BRB are clear (26), supporting
its use in the early stages of the disease. In humans, the
genetic background, environmental conditions, and age
are not as homogeneous as in animal models, and these
factors certainly impact on the outcome of the study.
Diabetes decreased occludin and claudin-5 content but
not the content of ZO-1. In mice, we reported that diabetes
decreased retinal ZO-1 levels after two weeks of diabetes
(18). A decrease in retinal ZO-1 levels was also found in
diabetic rats, although with a prolonged diabetes duration
(17). However, we found that diabetes disorganized ZO-1
distribution in retinal vessels, in a similar way as for
occludin. Occludin interacts with ZO-1, and it must dimer-
ize to form a four-helix bundle structure with ZO-1 (37),
which may account for a similar disorganization pattern
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FIG. 5. CaD prevents oxidative and nitrosative stress induced by diabetes. A: The oxidized proteins were detected using an anti-DNP antibody
by dot blot. A representative dot blot is shown above the graph. Data are presented as percentage of control and represent the mean  SEM of
3–4 animals. *P < 0.05, signiﬁcantly different from control; ANOVA (one-way) followed by Dunnett post hoc test. B: Representative images
showing nitrotyrosine immunoreactivity (green), which allows the detection of nitrated tyrosine residues, and nuclear DAPI staining (blue).
Magniﬁcation: 400, bar 50 m. GCL, ganglion cell layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear layer; CH,
choroidal layer. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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affected, at least for this time point. Previous studies also
showed that diabetes reduces occludin levels in retinal
vessels and disorganizes occludin in retinal vessels
(5,6,18). Barber and Antonetti did not ﬁnd a reduction in
claudin-5 levels (5), but they did not quantify claudin-5
levels in retinal extracts. Recently, two studies demon-
strated that claudin-5 expression and protein content are
decreased in the retinas of streptozotocin diabetic rats
(8,17), but for longer periods of diabetes. Therefore, our
data and these ﬁndings also point to an important role of
claudin-5 in the BRB breakdown induced by diabetes.
CaD totally prevented the alterations in tight junction
proteins, indicating that its protective effects against the
increase in BRB permeability are due to its stabilizing
effects on tight junction proteins (paracellular permeabil-
ity). It has been claimed that the increase in vesicular
transport (transcellular permeability) also contributes to
the increase in BRB permeability (8). However, vesicular
transport appears not to be affected by CaD, because it
was not able to prevent the increase in caveolin-1 immu-
noreactivity induced by diabetes.
The increase in ICAM-1 expression and leukostasis is
linked to the BRB breakdown (18,19,38,39). In retinas,
CaD totally prevented the increase in ICAM-1 levels, but
the increase in leukocyte adhesion was only partially
inhibited. This observation suggests that other players are
involved in leukocyte adhesion, which is probably not
substantially affected by CaD as ICAM-1 is. For instance,
in endothelial cell cultures, CaD per se decreased
ICAM-1 levels. These data clearly suggest that CaD
attenuates inﬂammatory processes occurring in diabetic
retinas, which have been considered key players in BRB
breakdown.
NF-B activation is known to mediate the expression of
cytokines and adhesion molecules, such as ICAM-1. In
fact, it was found that NF-B inhibition prevents the
increase in ICAM-1 levels, leukocyte adhesion, and BRB
leakage in diabetic retinas (20). Our results also suggest
that CaD prevented the increase in ICAM-1 levels, leuko-
cyte adhesion, and BRB leakage induced by diabetes, and
this was correlated with the inhibition of NF-B activation
by CaD.
The protective effects of CaD against the BRB break-
down might also be due to its modulation of VEGF levels
in the retina. VEGF is overexpressed in diabetic rat retinas
and is involved in BRB leakage and leukocyte adhesion
(40,41). CaD treatment decreases VEGF content in dia-
betic rats, and this observation was correlated with a
decrease in BRB permeability (26).
Oxidative stress plays a role in leukocyte adhesion and
BRB breakdown in the retinas of diabetic animals (18,42).
The protective effects of CaD can be explained by its
antioxidant properties. CaD is effective in scavenging
hydroxyl radicals in vitro (31). Moreover, CaD stabilizes
the BRB in diabetic rats, apparently because of its antiox-
idant action (26), and markedly reduces retinal edema
protecting diabetic rat retina against the oxidative stress
induced by ischemia/reperfusion (32). In this study, we
conﬁrmed that CaD decreases oxidative and nitrosative
stress, because it completely prevented the increase in
oxidized carbonyl groups and nitrotyrosine residues in
proteins induced by diabetes. Because oxidative stress
underlies inﬂammatory changes responsible for the BRB
breakdown, our observations further support the idea that
CaD vasoprotective effects might be mainly due to its
antioxidant properties.
The activation of p38 MAPK and NF-B pathways me-
diates BRB permeability in diabetic retinas (20,21). Also,
the inhibition of oxidative stress decreases p38 MAPK and
NF-B activation, and this was correlated with the preven-
tion of early changes in diabetic retinas (20,21,43). In
addition, evidences have shown that both p38 MAPK and
NF-B regulate tight junctions. The inhibition of p38
MAPK pathway improves the barrier function in epithelial
cells (44) and prevents tumor necrosis factor--induced
ZO-1 dislocation in bovine corneal endothelial cells (45).
Furthermore, tumor necrosis factor--mediated NF-B ac-
tivation decreases ZO-1 levels and distribution in intestinal
epithelial cells (46). In this work, we found that CaD
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FIG. 6. CaD inhibits the activation of p38 MAPK and NF-B in diabetic rat retinas. A: The activation of p38 MAPK was determined by Western
blotting, analyzing the phospho-p38/p38 MAPK ratio. A representative Western blot is shown above the graph. B: NF-B activation was
determined in retinal homogenates by ELISA (kit from Active Motif) using an antibody speciﬁc for the p65 subunit of NF-B. A secondary
antibody conjugated to horseradish peroxidase was used to quantify spectrophotometrically the activated form. Data are presented as percentage
of control and represent the mean  SEM of 6–7 animals. *P < 0.05, signiﬁcantly different from control; ANOVA (one-way) followed by Dunnett
post hoc test. #P < 0.05, signiﬁcantly different from diabetic animals; ANOVA (one-way) followed by Bonferroni post hoc test.
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retinas, and this was correlated with the inhibition of p38
MAPK and NF-B activation, as well as with the inhibition
of changes in tight junction proteins, thus suggesting that
the protective effects of CaD on paracellular permeability
appear to be due to the inhibition of oxidative stress and
consequently on p38 MAPK and NF-B activation.
In summary, in this work we shed light into the molec-
ular and cellular mechanisms underlying the protective
effect of CaD against retinal vascular leakage induced by
diabetes. CaD prevents changes in the content and distri-
bution of tight junction proteins, as well as changes in
ICAM-1 and leukocyte adhesion to retinal endothelial
cells. These protective effects appear to be linked to its
antioxidant effects, which prevent the activation of intra-
cellular signaling pathways and transcription factors, such
as p38 MAPK and NF-B. These data reinforce the use of
CaD in the treatment of diabetic retinopathy, particularly
in the early stages of the disease.
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